We have a robust pipeline of investigational therapies with the potential to address the unmet needs of patients living with ADHD, pain, addiction and diseases of the central nervous system (CNS).

With a proven track record in drug development, manufacturing and commercialization, we employ our industry-leading capabilities and proprietary technologies to uniquely solve some of the most intractable therapeutic challenges in these diseases and conditions.

Therapeutic Pipeline

Product

Indication

Preclinical

IND

Phase 1

Phase 2

Phase 3 / Pivotal

NDA

TRN-257

Narcolepsy

TRN-213

Spasticity

TRN-218

Pediatric ADHD

Cebranopadol

TRN-228

Acute pain

Chronic low back pain

Chronic neuropathic pain

Opioid addiction

TRN-261

Pain

Digital Health Pipeline

Device

Therapeutic Area

Preclinical

Pilot

Pivotal

510K

Commercial

First-in-Class, AI-Enhanced
Digital ADHD Diagnostic

ADHD

Therapeutic Pipeline

Preclinical

IND

Phase 1

Phase 2

Pivotal

NDA

Product: TRN-257
Indication: Narcolepsy
Stage: Phase 1

Product: TRN-213
Indication: Spasticity
Stage: Phase 2

Product: TRN-218
Indication: Pediatric ADHD
Stage: Phase 2

Cebranopadol
Product: TRN-228
Indication: Acute pain
Stage: Phase 2

Cebranopadol
Product: TRN-228
Indication: Chronic low back pain
Stage: Phase 2

Cebranopadol
Product: TRN-228
Indication: Chronic neuropathic pain
Stage: IND

Cebranopadol
Product: TRN-228
Indication: Opioid addiction
Stage: IND

Product: TRN-261
Indication: Pain
Stage: Phase 2

Digital Health Pipeline

Device: First-in-Class, AI-Enhanced Digital ADHD Diagnostic
Therapeutic Area: ADHD
Stage: Preclinical

We employ our industry-leading capabilities and proprietary technologies to uniquely solve some of the most intractable therapeutic challenges.